Optimi Health Provides Progress Report On Year Of Commercialization Post published:September 1, 2022 Post category:Press Release
Optimi Health Enters Into International Collaborative Research and Supply Agreement With Promises Innovative Recovery Center Post published:August 31, 2022 Post category:Press Release
Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional Mushroom Supplements and Appoints Chief Financial Officer to its Board of Directors Post published:August 25, 2022 Post category:Press Release
Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health Post published:August 16, 2022 Post category:Press Release
Optimi Health Unveils Canada’s First Natural Therapeutic Psilocybin Product For Approved Patients Post published:August 12, 2022 Post category:Press Release
Optimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient Advocate Thomas Hartle Post published:August 9, 2022 Post category:Press Release
Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre Post published:July 15, 2022 Post category:Press Release
Optimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMA Post published:June 29, 2022 Post category:Press Release
Optimi Health Requests Approval To Manufacture MDMA, Other Synthetic Psychedelics Post published:June 20, 2022 Post category:Press Release
Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access Program Post published:February 16, 2022 Post category:Press Release